Mineralys Therapeutics, Inc. (MLYS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $26.03: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 2.00; Below-average business quality.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone synthase inhibitor for hypertension and related cardiorenal conditions (CKD, OSA). An NDA was submitted in December 2025 with a PDUFA date of December 22, 2026;... Read more
Sell if holding. Engine safety override at $26.03: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 85d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Mineralys Therapeutics, Inc.
Latest news
- Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026 — benzinga May 18, 2026 positive
- AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios — benzinga May 18, 2026 neutral
- Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
- Mineralys Therapeutics Q1 EPS $(0.47), Inline — benzinga May 6, 2026 neutral
- TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating — benzinga Apr 27, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelorundrostat10-K Item 1A: 'We currently only have one product candidate, lorundrostat...Our business presently depends entirely on our ability to successfully obtain regulatory approval'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $26.03: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $24.41. Score 5.2/10, moderate confidence.
Take-profit target: $42.20 (+62.1% upside). Prior stop was $24.41. Stop-loss: $24.41.
Concentration risk — Pipeline: lorundrostat; Quality below floor (1.2 < 4.0); Value-trap signals (2/5): Margin compression (op margin -11.0%), High leverage (D/E 1.8).
Mineralys Therapeutics, Inc. trades at a P/E of N/A (forward -13.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover MLYS with a consensus score of 4.2/5. Average price target: $49.
What does Mineralys Therapeutics, Inc. do?Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone...
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone synthase inhibitor for hypertension and related cardiorenal conditions (CKD, OSA). An NDA was submitted in December 2025 with a PDUFA date of December 22, 2026; no approved products and no product revenue to date.